Clinical trial Recruiting at 1 site Interventional Ages 35 to 50

Tocotrienol Supplementation for Aging Markers in Healthy Middle-Aged Adults

Official title: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial Evaluating Tocotrienol-Rich Fraction as a Senolytic Agent in Middle-Aged Adults

Run by National University of Malaysia · NCT07637487 · Data updated 2026-11-12

Healthy adults aged 35–64 will take either tocotrienol or a placebo for 6 months to see if it can reduce cellular aging markers and improve health signals.

More Healthy Aging trials

Quick facts

Study typeInterventional
Ages35 Years to 50 Years
SexAll
Enrollment220 (estimated)
SponsorNational University of Malaysia
Academic / other
Locations1 site (Kuala Lumpur, Kuala Lumpur)
StatusRecruiting
StartedOctober 31, 2023
Main results expectedDecember 19, 2024
Study endsJanuary 30, 2027
Registry record updatedJune 9, 2026
Trial IDNCT07637487 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults aged 35–64 who are generally healthy by medical examination and not taking vitamin E supplements or palm oil–based products in the prior 3 months.

Probably not a fit

Individuals with chronic heart or related conditions, fat malabsorption, or significant liver or kidney dysfunction may not benefit and could be at risk.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study tests whether daily tocotrienol (200 mg) can influence aging-related biological pathways in otherwise healthy middle-aged adults. Participants will be randomized to receive either tocotrienol or a placebo for six months, with visits at baseline, 3 months, and 6 months for clinical assessments and laboratory testing. Outcomes include senescence-associated markers, inflammation, oxidative stress, and mitochondrial function, along with safety evaluations. The study compares a tocotrienol-rich fraction against placebo to determine potential effects on aging biomarkers and related health changes.

Why it matters

Potential benefit: If successful, tocotrienol could help modulate aging-related biological processes and potentially improve health markers in middle-aged adults.

How similar studies have gone: Previous research on senolytic approaches and vitamin E analogs suggests aging-biomarker effects are possible, but results are mixed and this appears to be a novel application.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Generally healthy as assessed by physical examination and blood lab test, including adequate liver and renal function, Neutrophil count \> 1500/mm3, Platelet count 120,000 - 450,000/mm3, Haemoglobin concentration 11.5 to 19.0g/dL for men; 10.5-17.5 g/dL for women, Prothrombin and partial thromboplastin time within normal range, ALT and AST \< 80 IU/L, Creatinine 0.7 to 1.3 mg/dL
* Subject of either gender, 35 to 64 years of age (inclusive)
* Not allergy to palm oil and vitamin E
* Do not take vitamin E supplements over the past 3 months
* Provide written informed consent prior to screening
* Subject is willing and able to comply with the study visit schedule and procedure, geographic proximity (investigator's discretion) that allows adequate follow up
* Subjects understand the study protocol and signed informed consent forms

Exclusion Criteria:

* Subjects with fat malabsorption
* Subjects with chronic conditions such as cardiac diseases (heart failure, myocardial infraction, ischemic heart disease), neurological diseases, diabetes, HIV infection, psychiatric illness/social situations
* Subjects with vegan diet
* Current smoker or used to smoke in the past 3 months
* Subject for surgery or had undergone surgery in the past 3 months
* Current or past history of drug, alcohol abuse and cancer
* Pregnant and lactating women
* History of bleeding tendencies or any condition predisposing to bleeding e.g. thrombocytopenia, abnormal liver function, liver disease (e.g. chronic hepatitis), gastrointestinal ulcers
* Any subject taking antibiotics or other medication or dietary supplement which could interfere with the action of tocotrienols
* Subjects who are pre-disposed to inherited blood/circulation disorders
* Subject who is taking anticoagulants and antithrombotic drugs, e.g. warfarin, aspirin, ticlopidine, heparin, etc.

Where it's running

  • National University of Malaysia
    Kuala Lumpur, Kuala Lumpur, Malaysia
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.